• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cardinal Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    11/6/25 4:13:37 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care
    Get the next $CAH alert in real time by email
    cah-20251105
    0000721371false00007213712025-11-052025-11-05

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): November 5, 2025
     
    Cardinal Health, Inc.
    (Exact Name of Registrant as Specified in Charter)
     
    Ohio 1-11373 31-0958666
    (State or Other Jurisdiction
    of Incorporation)
     (Commission
    File Number)
     (IRS Employer
    Identification No.)
    7000 Cardinal Place, Dublin, Ohio 43017
    (Address of Principal Executive Offices) (Zip Code)
    (614) 757-5000
    (Registrant’s telephone number, including area code)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common shares (without par value)CAHNew York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨





    Item 5.07.    Submission of Matters to a Vote of Security Holders.

    Cardinal Health, Inc. (the "Company") held its 2025 Annual Meeting of Shareholders (the "Annual Meeting") on November 5, 2025. See the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on September 16, 2025 (the “Proxy Statement”) for more information on the three proposals included in the Proxy Statement for the Annual Meeting.

    Proposal 1. The shareholders elected the 12 nominees listed below to the Company's Board of Directors, each to serve until the 2026 Annual Meeting of Shareholders and until their successor is duly elected and qualified or until their earlier resignation, removal from office or death, and voted as follows:
    NomineeForAgainstAbstainedBroker Non-Votes
    Robert W. Azelby185,554,4011,191,305421,26321,102,067
    Michelle M. Brennan185,052,8381,709,581404,55021,102,067
    Sheri H. Edison185,480,0291,078,030608,91021,102,067
    David C. Evans184,139,4302,596,591430,94821,102,067
    Patricia A. Hemingway Hall180,874,0955,683,892608,98221,102,067
    Jason M. Hollar185,671,2991,117,772377,89821,102,067
    Akhil Johri186,335,823346,745484,40121,102,067
    Gregory B. Kenny177,567,9499,181,392417,62821,102,067
    Nancy Killefer178,927,7687,589,047650,15421,102,067
    Christine A. Mundkur186,390,729322,976453,26421,102,067
    Robert W. Musslewhite186,367,331374,398425,24021,102,067
    Sudhakar Ramakrishna186,183,383512,015471,57121,102,067

    Proposal 2. The shareholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers ("say-on-pay" vote), and voted as follows:
    ForAgainstAbstainedBroker Non-Votes
    168,382,55417,271,1171,513,29821,102,067

    Proposal 3. The shareholders ratified the appointment of Ernst & Young LLP as the Company's independent auditor for the fiscal year ending June 30, 2026, and voted as follows:
    ForAgainstAbstainedBroker Non-Votes
    195,705,02012,253,800310,2160
    2


    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
      Cardinal Health, Inc.
    (Registrant)
    Date: November 6, 2025  By: /s/ Jessica L. Mayer
       Name: Jessica L. Mayer
       
    Title: Chief Legal and Compliance Officer

    3
    Get the next $CAH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAH

    DatePrice TargetRatingAnalyst
    6/3/2025$179.00Equal Weight → Overweight
    Wells Fargo
    2/5/2025$140.00 → $150.00Hold → Buy
    Jefferies
    1/8/2025$130.00 → $144.00Hold → Buy
    TD Cowen
    1/7/2025$140.00In-line → Outperform
    Evercore ISI
    1/6/2025$132.00 → $145.00Neutral → Buy
    BofA Securities
    12/13/2024$101.00 → $127.00Underweight → Equal Weight
    Wells Fargo
    12/4/2024$139.00Outperform
    Mizuho
    2/26/2024$125.00Outperform
    Leerink Partners
    More analyst ratings

    $CAH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Nov. 4, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on January 15, 2026 to shareholders of record at the close of business on January 2, 2026. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of

    11/4/25 4:45:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health completes acquisition of Solaris Health

    Adds the country's leading urology MSO with over 750 providers to Cardinal Health's leading multi-specialty MSO platform, The Specialty Alliance and brings Cardinal Health's MSO platforms to ~3,000 providers in 32 states DUBLIN, Ohio, Nov. 3, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that it has completed its acquisition of Solaris Health, the country's leading urology MSO. Solaris Health brings more than 750 providers across more than 250 practice locations in 14 states and adds immediate scale to the Urology Alliance within Cardinal Health's leading multi-specialty MSO platform, The Specialty Alliance.

    11/3/25 8:30:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Reports First Quarter Fiscal Year 2026 Results and Raises Outlook

    Revenue increased 22% to $64 billionGAAP1 operating earnings increased 18% to $668 million; GAAP diluted EPS increased 11% to $1.88Non-GAAP operating earnings increased 37% to $857 million, driven by segment profit growth across all five of the company's operating segments; non-GAAP diluted EPS increased 36% to $2.55Cardinal Health raises fiscal year 2026 non-GAAP EPS guidance2 to $9.65 to $9.85 and fiscal year 2026 non-GAAP adjusted free cash flow outlook to $3.0 to $3.5 billionCardinal Health anticipates completing the acquisition of Solaris Health in early NovemberDUBLIN, Ohio, Oct. 30, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported first quarter fiscal year 2026 revenues

    10/30/25 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ramakrishna Sudhakar was granted 1,067 shares, increasing direct ownership by 102% to 2,116 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    11/6/25 4:21:50 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Director Musslewhite Robert W was granted 1,067 shares, increasing direct ownership by 102% to 2,116 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    11/6/25 4:20:42 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Director Mundkur Christine was granted 1,067 shares, increasing direct ownership by 16% to 7,536 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    11/6/25 4:19:01 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    SEC Filings

    View All

    Cardinal Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - CARDINAL HEALTH INC (0000721371) (Filer)

    11/6/25 4:13:37 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form 10-Q filed by Cardinal Health Inc.

    10-Q - CARDINAL HEALTH INC (0000721371) (Filer)

    10/30/25 8:48:43 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CARDINAL HEALTH INC (0000721371) (Filer)

    10/30/25 6:52:52 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cardinal Health upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Cardinal Health from Equal Weight to Overweight and set a new price target of $179.00

    6/3/25 7:24:57 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health upgraded by Jefferies with a new price target

    Jefferies upgraded Cardinal Health from Hold to Buy and set a new price target of $150.00 from $140.00 previously

    2/5/25 7:09:45 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health upgraded by TD Cowen with a new price target

    TD Cowen upgraded Cardinal Health from Hold to Buy and set a new price target of $144.00 from $130.00 previously

    1/8/25 7:36:58 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Financials

    Live finance-specific insights

    View All

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Nov. 4, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on January 15, 2026 to shareholders of record at the close of business on January 2, 2026. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of

    11/4/25 4:45:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Reports First Quarter Fiscal Year 2026 Results and Raises Outlook

    Revenue increased 22% to $64 billionGAAP1 operating earnings increased 18% to $668 million; GAAP diluted EPS increased 11% to $1.88Non-GAAP operating earnings increased 37% to $857 million, driven by segment profit growth across all five of the company's operating segments; non-GAAP diluted EPS increased 36% to $2.55Cardinal Health raises fiscal year 2026 non-GAAP EPS guidance2 to $9.65 to $9.85 and fiscal year 2026 non-GAAP adjusted free cash flow outlook to $3.0 to $3.5 billionCardinal Health anticipates completing the acquisition of Solaris Health in early NovemberDUBLIN, Ohio, Oct. 30, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported first quarter fiscal year 2026 revenues

    10/30/25 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Aug. 15, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on October 15, 2025 to shareholders of record at the close of business on October 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator o

    8/15/25 4:40:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Leadership Updates

    Live Leadership Updates

    View All

    After Major Oncology Conference, All Eyes Turn to Industry Innovation

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

    6/12/25 9:00:00 AM ET
    $CAH
    $CTOR
    $CTXR
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Carlisle Companies Announces Leadership Appointments

    Carlisle Companies Incorporated (NYSE:CSL) today announced the appointment of Christopher B. Gaskill as Vice President & General Counsel for the Company. In conjunction with this appointment, Scott C. Selbach will transition to a new role as Executive Vice President, Government Relations for the Company. Mr. Selbach will also remain Secretary of the Company. Both Mr. Gaskill and Mr. Selbach will report to Chris Koch, Carlisle's Chair, President & Chief Executive Officer. Prior to joining Carlisle, Mr. Gaskill served as Executive Vice President, Chief Legal Officer, and Secretary at Summit Materials, Inc. (NYSE:SUM), where he was responsible for the company's global legal functions and ensu

    5/16/25 4:05:00 PM ET
    $CAH
    $CSL
    $SUM
    Other Pharmaceuticals
    Health Care
    Specialty Chemicals
    Industrials

    Robert Musslewhite and Sudhakar Ramakrishna to join Cardinal Health Board of Directors

    DUBLIN, Ohio, March 10, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert Musslewhite, former Chief Executive Officer of Definitive Healthcare Corp., and Sudhakar Ramakrishna, President and Chief Executive Officer of SolarWinds Corporation, as independent directors, effective March 7, 2025. With more than 20 years of leadership experience, including serving as CEO for two publicly traded companies, Mr. Musslewhite brings to the board unique expertise in advanced analytics, data, and technology across the healthcare e

    3/10/25 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    2/13/24 5:01:02 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    1/30/24 1:39:03 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    2/14/23 12:37:58 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care